Researchers asked ChatGPT to make treatment decisions for patients with severe aortic stenosis, comparing its answers to the recommendations of a full heart team. 

Researchers evaluated two techniques for predicting PPM after TAVR, comparing them to how cardiologists typically check for PPM in day-to-day practice. 

Catch up on key late-breaking research from Abbott, Edwards Lifesciences and Philips presented at the four-day meeting in Paris. 

Researchers evaluated data from more than 200 patients who underwent redo TAVR, noting that women and patients with a higher BMI faced a higher risk of coronary flow compromise.

It is still early for this new-look TAVR valve, but initial findings out of China include a procedural success rate of 100% and no deaths, disabling strokes or myocardial infarctions after 30 days. Read a full analysis from the team using the device. 

The new-look device gained CE mark approval in Europe in 2020, but it has not been approved yet in the United States.

Medtronic presented the real-world data at the PCR London Valves 2022 conference. The company's Evolut FX TAVR system gained FDA approval back in August 2021. 

The new findings, presented at the PCR London Valves 2022 conference, focused on mortality and heart failure hospitalization rates.